HER2-positive breast cancer and advanced stomach cancer are both treated with canmab injection, also referred to as tratuzumab. It is a monoclonal antibody that targets the overexpressed HER2 protein seen in some cancer cells. Canmab protects healthy cells while promoting the death of malignant cells by inhibiting HER2. Healthcare experts provide this injectable medicine, which is frequently used in conjunction with other therapies. Canmab has shown notable improvements in overall survival and disease-free survival in individuals with HER2-positive breast cancer. Infusion responses, cardiotoxicity, diarrhoea, nausea, and exhaustion are examples of frequent adverse effects. Before beginning treatment, patients should go over potential risks and benefits with their healthcare professional.
1. Breast cancer that is HER2-positive: Both early-stage and metastatic breast cancer are often treated with canmab injection.
2. For patients of advanced stomach cancer that are HER2-positive, it may also be used in conjunction with chemotherapy.
3. Adjuvant Therapy: To lower the risk of cancer recurrence in early-stage breast cancer, canmab can be administered as adjuvant therapy.
4. Testing for HER2 in tumour tissue establishes a patient's eligibility for Canmab therapy.
1. Canmab is a targeted therapy that exclusively targets cancer cells that overexpress HER2, sparing healthy cells in the process, which minimises side effects.
2. Treatment Results: It has demonstrated appreciable increases in disease-free survival and overall survival in patients with HER2-positive breast cancer.
3. Intravenous Infusion: Medical personnel often deliver canmab through intravenous infusion.
4. Personalised Care: Based on the type, stage, and general health of each patient, the dosage and administration of Canmab can be adjusted.
5. Canmab is frequently used in combination with other chemotherapeutic drugs or targeted therapies to increase the effectiveness of the treatment.
1. Reactions to Infusions: Some patients may encounter reactions to infusions, including fever, chills, and skin rashes.
2. Cardiotoxicity: Trastuzumab may result in problems with the heart, such as decreased heart function and heart failure.
3. Weakening of Heart Muscle: Trastuzumab has the potential to occasionally cause cardiomyopathy, a weakening of the heart muscle.
4. Diarrhoea: During treatment, gastrointestinal side effects, including diarrhoea, are possible.
5. Vomiting and Nausea: Some people may feel queasy or sick to their stomach.
6. Trastuzumab can cause neutropenia, which lowers white blood cell counts and raises the risk of infections.
7. Patients may feel weak or worn out while receiving treatment.
8. Trastuzumab may result in skin problems such as redness or itching.
Before beginning Canmab (Trastuzumab) medication, patients must talk with their doctor about any risks and side effects that could occur. The management of adverse effects and the safe and efficient use of this medicine can be achieved through routine monitoring and appropriate medical supervision during therapy.